irinotecan has been researched along with Allergy, Drug in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atasoy, A; Babacan, NA; Cihan, S; Kos, TF; Yildirim, Y | 1 |
| Abu-Amna, M; Bar-Sela, G; Hadad, S; Haim, N; Hassoun, G | 1 |
| Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Yamaguchi, T | 1 |
| Gemma, A; Kakihata, K; Kon, A; Nagashima, M; Suzuki, T; Yoshii, N | 1 |
| Chen, A; Chirmule, N; Gupta, S; Kaliyaperumal, A; Pennucci, JJ; Pérez-Ruixo, JJ; Starcevic, M; Swanson, SJ; Weeraratne, D; Wright, J; Wu, CY; Yang, BB; Zhang, K | 1 |
| Needle, MN | 1 |
| Fung, A; Viale, PH; Zitella, L | 1 |
2 review(s) available for irinotecan and Allergy, Drug
| Article | Year |
|---|---|
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cause of Death; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Costs; Drug Hypersensitivity; Drug Industry; Female; Fluorouracil; Humans; Irinotecan; Male; Medical Assistance; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Patient Education as Topic; Treatment Outcome; United States; Vomiting | 2005 |
2 trial(s) available for irinotecan and Allergy, Drug
| Article | Year |
|---|---|
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Hypersensitivity; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
Immunogenicity of panitumumab in combination chemotherapy clinical trials.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Hypersensitivity; Humans; Incidence; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Severity of Illness Index | 2011 |
3 other study(ies) available for irinotecan and Allergy, Drug
| Article | Year |
|---|---|
Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Neoplasms; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Hypersensitivity; Emergency Treatment; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome; Tumor Lysis Syndrome | 2015 |
Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Irinotecan in a Patient With Metastatic Colorectal Cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Irinotecan; Neoplasm Metastasis | 2015 |
Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Hypersensitivity; Female; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasms; Pneumonia; Product Surveillance, Postmarketing; Pulmonary Alveoli; Steroids; Tomography, X-Ray Computed | 2011 |